Alaunos Therapeutics, Inc. Common Stock
Market Cap
6.7M
Short interest (May 15)
0.3%
Net Short (Jun 03 ): -0.1%
Borrow Fee
1.76%
↑ 1.1%
Available Shares
80K
↓ 3.2%
Price Chart
Company Overview
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.